Search Results for: RAB5C

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CCR10 C-C motif chemokine receptor 10
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
Novel DGKI diacylglycerol kinase iota
  • Effects of PIP2 hydrolysis
  • alpha-Tocopherol succinate
Novel HOXB13 homeobox B13
Novel KRT15 keratin 15
  • Keratinization
  • Formation of the cornified envelope
Novel RAPGEFL1 Rap guanine nucleotide exchange factor like 1
Novel SLC27A2 solute carrier family 27 member 2
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 24-hydroxycholesterol
  • Alpha-oxidation of phytanate
  • Neutrophil degranulation
  • Peroxisomal protein import
  • Peroxisomal protein import
ALS2CL ALS2 C-terminal like
  • RAB GEFs exchange GTP for GDP on RABs
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Alzheimer's disease (AD)
APPL2 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2
EEA1 early endosome antigen 1
  • Toll Like Receptor 9 (TLR9) Cascade
  • Inositol 1,3-Bisphosphate
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
GLP1R glucagon like peptide 1 receptor
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • G alpha (s) signalling events
  • Glucagon-type ligand receptors
  • ADORA2B mediated anti-inflammatory cytokines production
  • Glucagon
  • Exenatide
  • Liraglutide
  • Albiglutide
  • Dulaglutide
  • Lixisenatide
  • Semaglutide
HRAS HRas proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • RAS GTPase cycle mutants
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Bladder cancer
  • Penile cancer
  • Squamous cell carcinoma
  • Thyroid cancer
  • Cervical cancer
  • Hepatocellular carcinoma
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
INCA1 inhibitor of CDK, cyclin A1 interacting protein 1
RABAC1 Rab acceptor 1
RBSN rabenosyn, RAB effector
  • Toll Like Receptor 9 (TLR9) Cascade
  • Factors involved in megakaryocyte development and platelet production
RIN2 Ras and Rab interactor 2
  • RAB GEFs exchange GTP for GDP on RABs
  • Macrocephaly, alopecia, cutis laxa, and scoliosis; MACS syndrome
RIN3 Ras and Rab interactor 3
  • RAB GEFs exchange GTP for GDP on RABs
SGSM3 small G protein signaling modulator 3
TBC1D15 TBC1 domain family member 15
  • TBC/RABGAPs

Page 1 out of 2 pages